Happy to share our @jama.com editorial published alongside the STArT trial! Our take: Acute pain and vaso-occlusion aren't always synonymous in SCD. Therapies should be tested where their target biology is driving disease. Precision trial design starts with matching mechanism to mechanism. #HemeSky
💬 Editorial by Shaniqua Anum, MD, and Julie Kanter, MD: Acute pain in #SickleCellDisease may reflect multiple mechanisms, and future #Arginine trials may need objective markers of organ injury or vascular occlusion to better identify treatment effects. ja.ma/3SDrOi2